MBX Biosciences, Inc. (MBX)
53.49
+0.39
(+0.73%)
USD |
NASDAQ |
Nov 18, 16:00
54.20
+0.71
(+1.33%)
After-Hours: 20:00
MBX Biosciences Enterprise Value : 2.158B for Nov. 17, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 17, 2026 | 2.158B |
| November 16, 2026 | 2.159B |
| November 13, 2026 | 2.299B |
| November 12, 2026 | 2.228B |
| November 11, 2026 | 2.387B |
| November 10, 2026 | 2.318B |
| November 09, 2026 | 2.205B |
| November 06, 2026 | 2.071B |
| November 05, 2026 | 1.927B |
| November 04, 2026 | 2.127B |
| November 03, 2026 | 2.252B |
| November 02, 2026 | 2.222B |
| October 30, 2026 | 2.295B |
| October 29, 2026 | 2.229B |
| October 28, 2026 | 2.210B |
| October 27, 2026 | 2.151B |
| October 26, 2026 | 2.018B |
| October 23, 2026 | 1.929B |
| October 22, 2026 | 2.027B |
| October 21, 2026 | 2.199B |
| October 20, 2026 | 2.177B |
| October 19, 2026 | 2.127B |
| October 16, 2026 | 1.984B |
| October 15, 2026 | 2.039B |
| October 14, 2026 | 1.945B |
| Date | Value |
|---|---|
| October 13, 2026 | 1.954B |
| October 12, 2026 | 2.104B |
| October 09, 2026 | 2.165B |
| October 08, 2026 | 2.165B |
| October 07, 2026 | 2.229B |
| October 06, 2026 | 2.347B |
| October 05, 2026 | 2.428B |
| October 02, 2026 | 2.426B |
| October 01, 2026 | 2.329B |
| September 30, 2026 | 2.432B |
| September 29, 2026 | 2.354B |
| September 28, 2026 | 2.344B |
| September 25, 2026 | 2.156B |
| September 24, 2026 | 2.241B |
| September 23, 2026 | 2.361B |
| September 22, 2026 | 2.557B |
| September 21, 2026 | 2.507B |
| September 18, 2026 | 2.601B |
| September 17, 2026 | 2.648B |
| September 16, 2026 | 2.537B |
| September 15, 2026 | 2.514B |
| September 14, 2026 | 2.437B |
| September 11, 2026 | 2.415B |
| September 10, 2026 | 2.507B |
| September 09, 2026 | 2.601B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Ligand Pharmaceuticals, Inc. | 6.579B |
| Xeris Biopharma Holdings, Inc. | 3.162B |
| ANI Pharmaceuticals, Inc. | 1.774B |
| Corcept Therapeutics, Inc. | 7.301B |
| Veru, Inc. | 13.38M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -62.42M |
| Total Expenses (Quarterly) | 62.42M |
| EPS Diluted (Quarterly) | -1.286 |
| Earnings Yield | -5.72% |
| Normalized Earnings Yield | -5.720 |